FibroBiologics (FBLG) Total Liabilities (2022 - 2026)
FibroBiologics (FBLG) posted quarterly Total Liabilities of $3.3 million for Q2 2026, down 74.76% year-over-year from $13.0 million in Q2 2025, and down 1.35% on a QoQ basis from $3.3 million in Q1 2026.
FibroBiologics (FBLG) Total Liabilities (2022 - 2026) Analysis & Trends
FibroBiologics has reported Total Liabilities for 5 years, with the latest figure at $3.3 million in Q2 2026.
- Total Liabilities for Q2 2026 came in at $3.3 million, down 74.76% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.3 million (down 74.76% YoY), and the FY2025 annual result was $3.5 million, down 74.74% from the prior year.
- Total Liabilities slipped to $3.3 million in Q2 2026, from $3.3 million in the prior quarter.
- Over five years, Total Liabilities peaked at $15.3 million in Q1 2024 and troughed at $3.3 million in Q2 2026.
- A 5-year average of $9.0 million and a median of $8.9 million in 2022 frame the typical range for Total Liabilities.
- The widest annual swing landed in 2024, when Total Liabilities rose 29.73%; it then sank 74.76% in 2026.
- A 5-year view of Total Liabilities shows it stood at $8.8 million in 2022, then climbed by 19.82% to $10.6 million in 2023, then grew by 29.73% to $13.7 million in 2024, then plunged by 74.74% to $3.5 million in 2025, then declined by 4.91% to $3.3 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $3.3 million in Q2 2026, $3.3 million in Q1 2026, and $3.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | FibroBiologics | 9.06 Mn | 9.06 Mn | - | 3.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.29 Mn |
| Mar 31, 2026 | 3.34 Mn |
| Dec 31, 2025 | 3.46 Mn |
| Sep 30, 2025 | 8.62 Mn |
| Jun 30, 2025 | 13.05 Mn |
| Mar 31, 2025 | 9.08 Mn |
| Dec 31, 2024 | 13.71 Mn |
| Sep 30, 2024 | 7.73 Mn |
| Jun 30, 2024 | 11.30 Mn |
| Mar 31, 2024 | 15.26 Mn |
| Dec 31, 2023 | 10.57 Mn |
| Dec 31, 2022 | 8.82 Mn |